- Home
- PGEN vs LADR Comparison
PGEN vs LADR Comparison
Compare PGEN & LADR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | LADR |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PGEN | LADR |
|---|---|---|
| Price | $6.25 | $9.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $8.33 | ★ $12.25 |
| AVG Volume (30 Days) | ★ 3.7M | 1.1M |
| Earning Date | 05-13-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 8.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $1,115.92 | $31.66 |
| Revenue Next Year | $81.04 | $16.92 |
| P/E Ratio | ★ N/A | $69.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $9.43 |
| 52 Week High | $6.04 | $11.92 |
Technical Indicators
Market Signals| Indicator | PGEN | LADR |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 40.51 |
| Support Level | $3.96 | N/A |
| Resistance Level | $6.04 | $10.42 |
| Average True Range (ATR) | 0.31 | 0.23 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 79.59 | 12.36 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About LADR Ladder Capital Corp
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.